Please login to the form below

Not currently logged in
Email:
Password:

Lilly hires new ACE president

Eli Lilly & Company veteran, Andrew Hotchkiss, is to become the company's president for the Australia, Canada and Europe (ACE) region

Eli Lilly & Company veteran, Andrew Hotchkiss, is to become the company's president for the Australia, Canada and Europe (ACE) region.

Hotchkiss takes over from Karim Bitar, and will lead company activities across the region, as Lilly seeks to deliver innovative developments tackling illnesses such as diabetes, heart disease, mental health and cancer. 

Andrew Hotchkiss
Andrew Hotchkiss

Hotchkiss was most recently vice president and international business unit leader for Lilly Oncology.

"I am proud and excited to have the opportunity to lead Lilly's hugely talented pool of dedicated employees across the region, who are focused on the mission to help improve outcomes for patients," said Hotchkiss.

Bryce Carmine, executive vice president and president, Lilly Bio-Medicines, also commented on the appointment: "[Hotchkiss] will be a tremendous asset to the organisation in leading our efforts to maximise the value of our marketed products and prepare Lilly's ACE region for the next wave of innovative Lilly medicines."

9th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics